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Background: Medication Overuse Headache (MOH) can be related in some patients to dependence-related
behaviour characterised by craving, a deficit in controlling substance intake, which is associated to orbitofrontal
cortex (OFC) dysfunction. The aim of this study was to explore the psychological correlates in MOH patients and
the functioning of the OFC through neuropsychological assessment (Iowa Gambling Task: IGT) and to relate it to
prognosis at a one year follow-up point.
Findings: Seventeen subjects suffering from probable MOH were included and compared to 19 migraineurs and to
17 controls. The results show significant between group differences for behavioural dependence, depression,
anxiety, catastrophizing. There were no between group differences for impulsivity. Mean IGT score did not allow
differentiation of MOH patients from the other groups, whereas the score was significantly different between opiate
abusers and other medication abusers (45 +/−5.7 versus 57.1 +/−8.2, p = 0.019). Among the clinical variables rated
at inclusion, the amount of acute headache medication taken per month was the only one predicting the
prognosis (RR = 1.05, 95% CI = 1-1.06, p = 0.04). A slight increase in risk of relapse at 1 year was observed in patients
with poorer IGT scores (RR = 0.92, 95% CI = 0.85-1, p = 0.05) and higher behavioural-dependence scores
(RR = 1.07, 95% CI = 1–1.14, p = 0.05). None of the other psychological variables predicted relapse risk.
Conclusions: These results must be interpreted with caution due to the low number of subjects. They showed a
deficit in decision making processes in MOH patients who overuse medications containing psychoactive substances
like opiates. Moreover dependence-related variables are related to the prognosis.
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The role of behavioural disorders and particularly an ad-
dictive component of behaviour in Medication Overuse
Headaches (MOH) is a matter of debate [1]. Orbitofron-
tal dysfunction is known to be at work in addictive be-
haviour. Indeed, orbitofrontal cortex is involved in the
ability to inhibit craving behaviour through decision ma-
king impairment [2,3]. Other psychological dimensions
may be implicated in dependence related behaviour in
MOH patients. In particular, MOH patients have been* Correspondence: francoise.radat@chu-bordeaux.fr
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in any medium, provided the original work is pshown to be at risk of depressive disorders and anxiety
disorders when compared to episodic migraine patients
[4]. Cupini and al. [5] emphasized the presence of ob-
sessive compulsive disorders in these patients as part of
the compulsive drug-seeking behaviour. In a one year
follow-up study anxiety and depression were not reliable
prognosis factors for MOH, in contrast to addictive be-
haviour [6]. Nevertheless, no study has focused on catas-
trophizing in MOH patients or on impulsivity while
those dimensions may be of interest in determining de-
pendence related behaviour.
Our objective was therefore to compare anxiety, de-
pression, catastrophizing and impulsivity dyscontrol as
well as decision-making impairment in MOH patients,
episodic migraine patients and healthy controls. Then, aOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Socio-demographic and clinical data within
groups
N = 17 N = 19 N = 17
MOH group EM group HC group
Gender
Male 4 5 4
Female 13 14 13
Age (years) 46.3 +/−10.7 46 +/−10 46.5 +/−10.5
Age of 1st occurrence
of migraine
17 +/−9 19.5 +/−12 -
Number of day with
headache/month
23.5 +/−7.1 2.5 +/−1.1 -
Number of tablets of acute
headache medication/month
82 [360–21] 6.2[16−1] -
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and neuropsychological variables to prognosis.
Methods
This is the clinical part of an imaging study implying
rest fMRI and 18F FDG PET. Results of the imaging
study will be presented elsewhere. The study was pro-
spective, non-randomised, comparing MOH evolving
from migraine patients to episodic migraine sufferers
(EM) and to healthy volunteers without headache (HV).
MOH and EM patients have been followed up over one
year. Patients asking for a consultation at the neuro-
logical department at the University Hospital in Bor-
deaux were included if they fulfilled migraine diagnostic
criteria (ICHD-II 1.1 and 1.2) or probable MOH diag-
nostic criteria (ICHD-II 8.2) with prior migraine and if
they were 18 years old or more. A prior episode of
MOH was an exclusion criteria for the migraine group
The healthy volunteers were recruited among Bordeaux
University Hospital staff members.
Clinical data collection comprised a standardized inter-
view process inquiring for crisis frequency and medication
intake frequency during the last three months and acute
and prophylactic antimigraine drugs currently used.
Patients from the EM and MOH groups were given a
headache diary, recording days with headache and acute
headache medication intake during the follow-up period.
All subjects answered self-administered questionnaires. In
order to assess depression, the Beck Depression Inventory
((BDI-13 items) [7] was used. Anxiety was assessed using
the State Trait Anxiety Inventory (STAI-state) [8]. Catas-
trophizing was assessed using the Pain Catastrophizing
Scale (PCS) [9]. The Barratt Impulsiveness Scale (BIS- 11)
[10] is a self-report measure of impulsive personality
traits. The Medication Dependence Questionnaire for
Headache sufferers (MDQ-H) [11] is a rating scale
assessing dependence to medication in headache pa-
tients. Then, all subjects underwent IGT [12], a
computerised task which is a test aiming to detect
decision-making impairment. It is a test where the
subject is confronted with a decision that involves a
conflict between an immediate reward and a long term
negative consequence. The lower the score achieved, the
poorer the decision-making performance is.
Subjects from the MOH group underwent either an
inpatient or outpatient withdrawal procedure. MOH and
EM groups were re-examined at 12 months from inclu-
sion. Patients from the MOH group were classified in a
binary way as relapse or non relapse depending on whe-
ther they fulfilled ICHD-II criteria for MOH at month
twelve visit.
Statistical analysis was performed using SPSS version
17.0 software. Descriptive analysis was performed and
the differences between groups were tested using chisquare and a one-way analysis of variance when ap-
propriate. In order to compare the score results obtained
by the questionnaires and the IGT between the three
groups a one-way analysis of variance was also used, and
t-test was used to compare groups in pairs. Logistic re-
gression analysis was performed in order to predict re-
lapse within one year. For the patients that have been
followed up during one year, scores evolution was tested
using paired t-test.
Findings
Fifty-one subjects were included in the study: 17 patients
suffering from MOH, 19 EM 17 HV.
Sociodemographic characteristics of participants are
presented in Table 1.The three groups were comparable
for sex, age, family situation and work status.
The mean number of days with headaches was
23.5 +/− 7.1 in the MOH group and 2.5 +/−1.1 in the
EM group. The mean duration of MOH was 6.8 years;
duration ranged from 4 months to 30 years. The acute
headache medication overused by MOH patients are
shown in Table 2. Five patients were overusing either
opiates or a combination of analgesics containing opiates
derivates. The total amount of acute headache medica-
tion taken per month was 82 [360–21] in the MOH
group and 6.2 [1] in the EM group.
The mean scores obtained in each questionnaire as-
sessing the psychological dimension in each groups are
presented in Table 3. The results show that mean scores
were higher in MOH than in EM and HV for depen-
dence (MDQ-H), depression (BDI), anxiety (STAI), ca-
tastrophizing (PCS). The between groups analysis of
variance for anxiety (STAI)) and depression (BDI) in-
dicated a significant statistical group effect (F = 5,7,
p = 0;006 ; F = 6;3, p = 0;003). On the contrary, there
were no between group differences for impulsivity (BIS).
Total raw scores for IGT did not allow to differentiate
MOH patients (IGT total raw score score = 26.2+/−24.8)
Table 2 Acute headache medication overused by MOH
patients
ICHD 2 diagnosis n
Triptan (ICHD-2: 8.2.2) 4
Analgesic (ICHD-2: 8.2.3) 2
Opioid (ICHD 2: 8.2.4) 2
Combination analgesic (ICHD 2: 8.2.5) 1














MOH Opiate- MOH opiate+
Figure 1 IGT row score in opiate abusers and non opiate
abusers in the MOH group.
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teers without headache (14.7 +/−30.4) whereas within the
MOH group there was a significant difference between
opiate abusers and other medication abusers (4+/−18.9
versus 32.8 +/−26.5, p = 0.028) (Figure 1). When compar-
ing MOH patients to EM patients, only MDQ-H and PCS
scores were significantly different, whereas when compa-
ring MOH to HV, MDQ-H, PCS, BDI and STAI scores
were significantly different (Table 2).
Among the clinical variables rated at inclusion, the
number of acute headache medication units taken per
month was the only one predicting the prognosis (RR =
1.05, 95% CI = 1-1.06, p = 0.04). A slight increase in risk
of relapse at 1 year was observed in patients with poorer
IGT raw scores (RR = 0.92, 95% CI = 0.85-1, p = 0.05)
and higher MDQ-H scores (RR = 1.07, 95% CI = 1–1.14,
p = 0.05). None of the other psychological variables pre-
dicted relapse risk.
For the MOH group a one year a significant decrease
was observed for MDQ-H (t = 5,7, p < 0,000) and for
PCS (t = 3,7, p = 0,003) and for the EM groups no signifi-
cant differences were observed.
Discussion
To summarise, this study showed between group dif-
ferences for anxiety, depression, catastrophizing andTable 3 MDH-Q, BDI, STAI, PCS, BIS and IGT scores within gro
MOH, n = 17 EM, n = 1
MDH-Q 85.2 +/−24 [47–133]*§ 35.3 +/−1
BDI 5.2 +/−4.2 [0–12]§§ 3.5 +/−3.
STAI 40.5 +/−10.4 [22–56]§§§ 35.8 +/−9
PCS 28.3 +/−12.5 [10–51]**§ 20.3 +/−1
BIS 58 +/−7.7 [40–73] 57.2+/−9
IGT total raw score 26.2 +/−24.8 29.5 +/−2
MOH vs EM: *:p < 0.000, **:p = 0.05.
MOH vs HV: § p < 0.000, §§ p = 0.001, §§§p = 0.002.
EM vs HV: ° p < 0.000, °° p = 0.01, °°° p = 0.04.behavioural dependence but not for impulse dyscontrol
and decision-making impairment. However, MOH with
opioid medication overuse exhibited a significant dis-
turbance in decision making when compared with MOH
overusing other acute headache medication. Moreover de-
pendence related behaviour and decision-making impair-
ment at inclusion weakly predicted one year prognosis in
MOH whereas other variables did not.
Catastrophizing has been reported to be associated
with a higher risk of prescription opioid abuse in pain
patients [13,14]. In the field of headaches, it has been
showed that subjects with chronic daily headaches ex-
hibit increased catastrophizing scores when compared to
episodic migraineurs, higher catastrophizing being asso-
ciated with lower quality of life [15]. Moreover the pre-
vention of MOH in high frequency migraine patients by
a cognitive behavioural program is associated with a
lowering of catastrophizing [16].
There are a few studies examining psychological fac-
tors as predictors of prognosis in MOH patients. Theups
9 HV, n = 17 F, p
2.6 [9–63]° 21.7+/−1.9 [21–29] F = 78.6, p < 0.000
9 [0–13] °° 1.0+/−1.3 [0–4] F = 6.3, p = 0.003
.8 [20–60]°°° 29.4+/−8.5[21–53] F = 5.7, p = 0.006
2 [0–38]∞ 4.8+/−6 [0–51] F = 21.3, p < 0.000
.8 [42–85] 59 +/−6.7 [51–74] F = 0.226, NS
9.7 14.7 +/−30.4 F = 1.25, NS
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pendence scores (SDS) predict 2 to 3 year prognosis
after detoxification [17]. Smoking, alcohol consumption
and the doses of antimigraine drugs used allowed to pre-
dict one year follow-up relapse in detoxified MOH but
not in anxiety disorders or affective disorders [6]. In a
one year follow-up study of 72 subjects with MOH from
the general population Fontanillas showed that opioid
abuse was associated with a bad prognosis [18]. In this
direction, our results confirm that the dependence re-
lated behaviour is a stronger predictor of prognosis than
emotional disturbances. Indeed, despite the small size of
the sample, the amount of acute headache medication
taken and the MDQ-H score at inclusion significantly
predicted prognosis at one year whereas all emotional
measures did not.
The IGT allows to measure the ability to defer imme-
diate reward, taking into account the long term negative
consequences, and it is altered in prefrontal-damaged
patients. In a sample of MOH patients, Biagianti and al
[19] showed a statistically significant deficit in IGT net
score compared to healthy matched controls. Patients
were retested one year later and IGT performance re-
mained negative. The IGT score did not allow to predict
relapse in medication overuse after detoxification [20].
In a similar vein, Gomez-Beldarrain evaluated orbito-
frontal impairment using other neuropsychological tasks.
They found a significant impairment in the orbito-
frontal tasks performance in MOH compared with
controls. Moreover, in the one year follow-up this per-
formance predicted relapse in MOH. Our study failed to
demonstrate any difference between MOH and the two
controls groups despite a slightly lower performance in
MOH than in episodic migraineurs. Our healthy control
sample clearly exhibited a lack of motivation when
performing the task. On the other hand, the comparison
between opiate overusers and other medication over-
users showed a significant difference between the two
groups on the IGT total net score. This result can be
put into parallel with the fact that in Fumal’s sample of
MOH patients, the hypofunctioning of the orbito-frontal
cortex showed with PET was due to the subsample of
patients overusing opiates [21]. Among the MOH sam-
ple, the IGT total net score predicted the prognosis at a
one year follow up visit confirming the previously cited
studies.
The strength of this study is its one year prospective
design, the assessment of rarely explored psychological
dimensions such as impulsivity and catastrophizing. The
major weaknesses are the small number of subjects and
the motivation failure in the healthy controls, thereby it
would be very usefull to present further resuklts with
more subjects. Nevertheless the study allows to confirm
the utmost importance of dependence related behaviouraldisturbance in characterising MOH patients. Moreover it
seems determinant for prognosis in an illness characte-
rised by its poor prognosis. These results lead us to advise
strong management of the psychological dimension in
MOH patients. Cognitive behavioural therapies in particu-
lar can address catastrophizing, emotional disorders and
impulse dyscontrol and motivational interviewing should
be part of the management of the dependence related
behaviours.
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